References
- AltshulerDLDurbinRMAbecasisGRA map of human genome variation from population-scale sequencingNature201046773191061107320981092
- FrazerKABallingerDGCoxDRA second generation human haplotype map of over 3.1 million SNPsNature2007449716485186117943122
- ChanockSJManolioTBoehnkeMReplicating genotype-phenotype associationsNature2007447714565566017554299
- SimSCIngelman-SundbergMPharmacogenomic biomarkers: new tools in current and future drug therapyTrends Pharmacol Sci2011322728121185092
- LeeSYMcLeodHLPharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical applicationJ Pathol20112231152720818641
- WangLMcLeodHLWeinshilboumRMGenomics and drug responseN Engl J Med2011364121144115321428770
- HoggattJPersonalized medicine–trends in molecular diagnostics: exponential growth expected in the next ten yearsMol Diagn Ther2011151535521469770
- McCarrollSAKuruvillaFGKornJMIntegrated detection and population-genetic analysis of SNPs and copy number variationNat Genet200840101166117418776908
- FanJBGundersonKLBibikovaMIllumina universal bead arraysMethods Enzymol2006410577316938546
- HellerTKirchheinerJArmstrongVWAmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotypingTher Drug Monit200628567367717038884
- BurmesterJKSedovaMShaperoMHMansfieldEDMET microarray technology for pharmacogenomics-based personalized medicineMethods Mol Biol20106329912420217574
- PodderMRuanJTrippBWChuZETebbuttSJRobust SNP genotyping by multiplex PCR and arrayed primer extensionBMC Med Genomics20081518237385
- SchrijverIOitmaaEMetspaluAGardnerPGenotyping microarray for the detection of more than 200 CFTR mutations in ethnically diverse populationsJ Mol Diagn20057337538716049310
- VairavanRAutoGenomics, IncPharmacogenomics20045558558815212595
- DunbarSAApplications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detectionClin Chim Acta20063631–2718216102740
- BaoYPHuberMWeiTFMarlaSSStorhoffJJMullerURSNP identification in unamplified human genomic DNA with gold nanoparticle probesNucleic Acids Res2005332e1515659576
- UmekRMLinSWVielmetterJElectronic detection of nucleic acids: a versatile platform for molecular diagnosticsJ Mol Diagn200132748411333303
- PetterssonELundebergJAhmadianAGenerations of sequencing technologiesGenomics200993210511118992322
- Fakhrai-RadHPourmandNRonaghiMPyrosequencing: an accurate detection platform for single nucleotide polymorphismsHum Mutat200219547948511968080
- WheelerDASrinivasanMEgholmMThe complete genome of an individual by massively parallel DNA sequencingNature2008452718987287618421352
- FujimotoANakagawaHHosonoNWhole-genome sequencing and comprehensive variant analysis of a Japanese individual using massively parallel sequencingNat Genet2010421193193620972442
- MetzkerMLSequencing technologies – the next generationNat Rev Genet2010111314619997069
- WelchJSWesterveltPDingLUse of whole-genome sequencing to diagnose a cryptic fusion oncogeneJAMA2011305151577158421505136
- AshleyEAButteAJWheelerMTClinical assessment incorporating a personal genomeLancet201037597251525153520435227
- MarguliesMEgholmMAltmanWEGenome sequencing in microfabricated high-density picolitre reactorsNature2005437705737638016056220
- BentleyDRBalasubramanianSSwerdlowHPAccurate whole human genome sequencing using reversible terminator chemistryNature20084567218535918987734
- LivakKJAllelic discrimination using fluorogenic probes and the 5′ nuclease assayGenet Anal1999145–614314910084106
- WittwerCTHerrmannMGGundryCNElenitoba-JohnsonKSReal-time multiplex PCR assaysMethods200125443044211846612
- LyonEWittwerCTLightCycler technology in molecular diagnosticsJ Mol Diagn20091129310119196999
- El HelaliNNguyenJCLyAGiovangrandiYTrinquartLDiagnostic accuracy of a rapid real-time polymerase chain reaction assay for universal intrapartum group B streptococcus screeningClin Infect Dis200949341742319580414
- BoehmeCCNabetaPHillemannDRapid molecular detection of tuberculosis and rifampin resistanceN Engl J Med2010363111005101520825313
- GibsonNJThe use of real-time PCR methods in DNA sequence variation analysisClin Chim Acta20063631–2324716182268
- LittleDPBraunAO’DonnellMJKosterHMass spectrometry from miniaturized arrays for full comparative DNA analysisNat Med1997312141314169396615
- OethPdel MistroGMarnellosGShiTvan den BoomDQualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY)Methods Mol Biol200957830734319768603
- WrightWTHeggartySVYoungISMultiplex MassARRAY spectrometry (iPLEX) produces a fast and economical test for 56 familial hypercholesterolaemia-causing mutationsClin Genet200874546346818700895
- SyvanenACAccessing genetic variation: genotyping single nucleotide polymorphismsNat Rev Genet200121293094211733746
- PourzandCCeruttiPGenotypic mutation analysis by RFLP/PCRMutat Res199328811131217686255
- NewtonCRGrahamAHeptinstallLEAnalysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)Nucleic Acids Res1989177250325162785681
- LyamichevVMastALHallJGPolymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probesNat Biotechnol199917329229610096299
- RiedlingerJBeqajSHMilishMAMulticenter evaluation of the BD Max GBS assay for detection of group B streptococci in prenatal vaginal and rectal screening swab specimens from pregnant womenJ Clin Microbiol201048114239424120826650
- LittleSFDA regulations and novel molecular diagnostic testsClin Lab Int200674849
- US Food and Drug AdministrationTable of pharmacogenomic biomarkers in drug labels Updated July 27, 2011. Available from: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed May 2, 2011.
- US Food and Drug AdministrationIVD: in vitro diagnostic product database Updated 29 July, 2011.Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfivd/index.cfm. Accessed May 2, 2011.
- SconceEAKhanTIWynneHAThe impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenBlood200510672329233315947090
- LanhamKJOestreichJHDunnSPSteinhublSRImpact of genetic polymorphisms on clinical response to antithromboticsPharmacogenomics Pers Med201038799
- GongIYTironaRGSchwarzUIProspective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapyBlood712011 [Epub ahead of print.]
- WadeliusMChenLYErikssonNAssociation of warfarin dose with genes involved in its action and metabolismHum Genet20071211233417048007
- NanosphereVerigene Warfarin Metabolism Nucleic Acid Test (IVD)2010 Available from: http://www.nanosphere.us/verigenewarfarinmetabolismnucleicacidtest_4472.aspx. Accessed May 23, 2011.
- GenMark Dx. eSensor® Warfarin Sensitivity Test. 2010. Available from: http://www.genmarkdx.com/products/reagents/warfarin.php. Accessed May 23, 2011.
- Van SchieRMWadeliusMIKamaliFGenotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial designPharmacogenomics200910101687169519842940
- MauriceCBBaruaPKSimsesDSmithPHoweJGStackGComparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotypingClin Chim Acta201041113–1494795420226775
- LangleyMRBookerJKEvansJPMcLeodHLWeckKEValidation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithmsJ Mol Diagn200911321622519324988
- MegaJLSimonTColletJPReduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysisJAMA2010304161821183020978260
- SimonTVerstuyftCMary-KrauseMGenetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med2009360436337519106083
- EllisKJStoufferGAMcLeodHLLeeCRClopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendationsPharmacogenomics200910111799181719891556
- PareGMehtaSRYusufSEffects of CYP2C19 genotype on outcomes of clopidogrel treatmentN Engl J Med2010363181704171420979470
- SwenJJNijenhuisMde BoerAPharmacogenetics: from bench to byte – an update of guidelinesClin Pharmacol Ther201189566267321412232
- NedRMGenetic testing for CYP450 polymorphisms to predict response to clopidgrel: current evidence and test availability. Application: pharmacogenomicsPLoS Curr20102RRN118020877456
- LeeCCMcMillinGABabicNMelisRYeoKTEvaluation of a CYP2C19 genotype panel on the GenMark eSensor(R) platform and the comparison to the Autogenomics Infiniti and Luminex CYP2C19 panelsClin Chim Acta201141211–121133113721385571
- Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J20055161315492763
- De GregoriMAllegriMDe GregoriSHow and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatmentsCurr Drug Metab201011327628221171195
- BrockmollerJKirchheinerJSchmiderJThe impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatmentClin Pharmacol Ther200272443845212386646
- de LeonJSusceMTPanRMFairchildMKochWHWedlundPJThe CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuationJ Clin Psychiatry2005661152715669884
- HoskinsJMCareyLAMcLeodHLCYP2D6 and tamoxifen: DNA matters in breast cancerNat Rev Cancer20099857658619629072
- FleemanNDundarYDicksonRCytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analysesPharmacogenomics J201111111420877299
- InnocentiFUndeviaSDIyerLGenetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecanJ Clin Oncol20042281382138815007088
- RouitsEBoisdron-CelleMDumontAGuerinOMorelAGamelinERelevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patientsClin Cancer Res200410155151515915297419
- MarshSHoskinsJMIrinotecan pharmacogenomicsPharmacogenomics20101171003101020602618
- FordLTBergJDThiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has comeJ Clin Pathol201063428829520354201
- ZhouSClinical pharmacogenomics of thiopurine S-methyltransferaseCurr Clin Pharmacol20061111912818666383
- MallalSNolanDWittCAssociation between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirLancet2002359930872773211888582
- US Food and Drug Administration7242008Information on abacavir (marketed as Ziagen) and abacavir-containing medications Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm094302.htm. Accessed May 23, 2011.
- MallalSPhillipsECarosiGHLA-B*5701 screening for hypersensitivity to abacavirN Engl J Med2008358656857918256392
- SaagMBaluRPhillipsEHigh sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patientsClin Infect Dis20084671111111818444831
- FranciottaDKwanPPeruccaEGenetic basis for idiosyncratic reactions to antiepileptic drugsCurr Opin Neurol200922214414919262378
- ChungWHHungSIHongHSMedical genetics: a marker for Stevens-Johnson syndromeNature2004428698248615057820
- US Food and Drug Administration January 31, 2008. Information on carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics) with FDA alerts. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProvid-ers/ucm107834.htm. Accessed May 23, 2011.
- AhlenstielGBoothDRGeorgeJIL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practiceJ Gastroenterol201045990391020635099
- RauchAKutalikZDescombesPGenetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association studyGastroenterology201013841338134520060832
- TanakaYNishidaNSugiyamaMGenome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis CNat Genet200941101105110919749757
- GeDFellayJThompsonAJGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature2009461726239940119684573
- ThomasDLThioCLMartinMPGenetic variation in IL28B and spontaneous clearance of hepatitis C virusNature2009461726579880119759533
- LiJWangLMamonHKulkeMHBerbecoRMakrigiorgosGMReplacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testingNat Med200814557958418408729
- GazdarAFActivating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene200928Suppl 1S24S3119680293
- VakianiESolitDBKRAS and BRAF: drug targets and predictive biomarkersJ Pathol2011223221922921125676
- FlahertyKTPuzanovIKimKBInhibition of mutated, activated BRAF in metastatic melanomaN Engl J Med2010363980981920818844
- DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature2002417689294995412068308
- Dias-SantagataDAkhavanfardSDavidSSRapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicineEMBO Mol Med20102514615820432502
- KimSMisraASNP genotyping: technologies and biomedical applicationsAnnu Rev Biomed Eng2007928932017391067
- WuAHBBabicNYeoKTJImplementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorianPer Med200963315327
- KiechleFLHollandCAPoint-of-care testing and molecular diagnostics: miniaturization requiredClin Lab Med200929355556019840687